New combo therapy shows promise for hard-to-treat childhood cancers
NCT ID NCT03445858
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a mix of two drugs (pembrolizumab and decitabine) plus targeted radiation in 22 children and young adults whose solid tumors or lymphoma had returned or stopped responding to treatment. The main goals were to see if the combination was safe and tolerable, and to get an early look at whether it could shrink tumors. The study was completed, but results are not yet widely reported.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma
- Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- Card game aims to ease tough End-of-Life talks for cancer patients
- New drug shows promise for stubborn cancers
- New MET inhibitor DO-2 enters human trials for Hard-to-Treat cancers
- Targeted drug takes aim at NF1-Mutated cancers